Radiofrequency ablation of small renal cortical tumours in healthy adults

Renal function preservation and intermediate oncological outcome

Joshua M. Stern, Amit Gupta, Jay D. Raman, Nicholas Cost, Steven Lucas, Yair Lotan, Ganesh V. Raj, Jeffrey A. Cadeddu

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

OBJECTIVES To present the glomerular filtration rate (GFR) and oncological outcomes in a series of patients with cT1a renal cortical tumours treated with radiofrequency ablation (RFA), a non-ischaemic minimally invasive ablative method, as nephron-sparing surgery gives excellent oncological outcomes and preserves renal function. PATIENTS AND METHODS Healthy (American Society of Anesthesiologists, ASA, I and II) patients with cT1a renal masses were identified, and clinical and radiographic data were reviewed to assess indications, complications, radiological evidence of disease recurrence, and renal function. Changes in GFR were calculated. Radiological recurrence was defined as any new enhancement (>10 Hounsfield units) after absence of enhancement on initial 6-week computed tomography. RESULTS Four patients were ASA I and 59 were ASA II; the median (range) age was 58 (20-84.6) years and the lesion diameter 2.1 (1-4.0) cm. Preoperative needle biopsy was diagnostic in 89% of patients, including 75% diagnostic of renal cell carcinoma (RCC). At a median (range) follow-up of 34 (1.0-80) months the renal preservation rate was 97%. One patient had a nephrectomy for biopsy-confirmed recurrence of RCC at 55 months; a second had a nephrectomy at 24 months for suspected radiographic recurrence, but had no evidence of disease on final pathology. A fifth (20%) of the patients had chronic kidney disease at the time of diagnosis. The median GFR before and after RFA was 76.3 and 74.3 mL/min/m2 (difference 2.0 mL/min/m2). CONCLUSION RFA might be a reasonable treatment choice for the healthy patient, with appropriate informed consent. Intermediate results suggest excellent oncological outcomes and preservation of renal function.

Original languageEnglish (US)
Pages (from-to)786-789
Number of pages4
JournalBJU International
Volume104
Issue number6
DOIs
StatePublished - Sep 2009
Externally publishedYes

Fingerprint

Kidney
Glomerular Filtration Rate
Neoplasms
Recurrence
Nephrectomy
Renal Cell Carcinoma
Nephrons
Needle Biopsy
Informed Consent
Chronic Renal Insufficiency
Tomography
Pathology
Biopsy
Therapeutics

Keywords

  • Cell death
  • NADH diaphorase
  • Pathology
  • Renal cell carcinoma
  • RFA

ASJC Scopus subject areas

  • Urology

Cite this

Radiofrequency ablation of small renal cortical tumours in healthy adults : Renal function preservation and intermediate oncological outcome. / Stern, Joshua M.; Gupta, Amit; Raman, Jay D.; Cost, Nicholas; Lucas, Steven; Lotan, Yair; Raj, Ganesh V.; Cadeddu, Jeffrey A.

In: BJU International, Vol. 104, No. 6, 09.2009, p. 786-789.

Research output: Contribution to journalArticle

Stern, Joshua M. ; Gupta, Amit ; Raman, Jay D. ; Cost, Nicholas ; Lucas, Steven ; Lotan, Yair ; Raj, Ganesh V. ; Cadeddu, Jeffrey A. / Radiofrequency ablation of small renal cortical tumours in healthy adults : Renal function preservation and intermediate oncological outcome. In: BJU International. 2009 ; Vol. 104, No. 6. pp. 786-789.
@article{78393b1d4ad64cf2b6d5e2ba4fd4fa96,
title = "Radiofrequency ablation of small renal cortical tumours in healthy adults: Renal function preservation and intermediate oncological outcome",
abstract = "OBJECTIVES To present the glomerular filtration rate (GFR) and oncological outcomes in a series of patients with cT1a renal cortical tumours treated with radiofrequency ablation (RFA), a non-ischaemic minimally invasive ablative method, as nephron-sparing surgery gives excellent oncological outcomes and preserves renal function. PATIENTS AND METHODS Healthy (American Society of Anesthesiologists, ASA, I and II) patients with cT1a renal masses were identified, and clinical and radiographic data were reviewed to assess indications, complications, radiological evidence of disease recurrence, and renal function. Changes in GFR were calculated. Radiological recurrence was defined as any new enhancement (>10 Hounsfield units) after absence of enhancement on initial 6-week computed tomography. RESULTS Four patients were ASA I and 59 were ASA II; the median (range) age was 58 (20-84.6) years and the lesion diameter 2.1 (1-4.0) cm. Preoperative needle biopsy was diagnostic in 89{\%} of patients, including 75{\%} diagnostic of renal cell carcinoma (RCC). At a median (range) follow-up of 34 (1.0-80) months the renal preservation rate was 97{\%}. One patient had a nephrectomy for biopsy-confirmed recurrence of RCC at 55 months; a second had a nephrectomy at 24 months for suspected radiographic recurrence, but had no evidence of disease on final pathology. A fifth (20{\%}) of the patients had chronic kidney disease at the time of diagnosis. The median GFR before and after RFA was 76.3 and 74.3 mL/min/m2 (difference 2.0 mL/min/m2). CONCLUSION RFA might be a reasonable treatment choice for the healthy patient, with appropriate informed consent. Intermediate results suggest excellent oncological outcomes and preservation of renal function.",
keywords = "Cell death, NADH diaphorase, Pathology, Renal cell carcinoma, RFA",
author = "Stern, {Joshua M.} and Amit Gupta and Raman, {Jay D.} and Nicholas Cost and Steven Lucas and Yair Lotan and Raj, {Ganesh V.} and Cadeddu, {Jeffrey A.}",
year = "2009",
month = "9",
doi = "10.1111/j.1464-410X.2009.08443.x",
language = "English (US)",
volume = "104",
pages = "786--789",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Radiofrequency ablation of small renal cortical tumours in healthy adults

T2 - Renal function preservation and intermediate oncological outcome

AU - Stern, Joshua M.

AU - Gupta, Amit

AU - Raman, Jay D.

AU - Cost, Nicholas

AU - Lucas, Steven

AU - Lotan, Yair

AU - Raj, Ganesh V.

AU - Cadeddu, Jeffrey A.

PY - 2009/9

Y1 - 2009/9

N2 - OBJECTIVES To present the glomerular filtration rate (GFR) and oncological outcomes in a series of patients with cT1a renal cortical tumours treated with radiofrequency ablation (RFA), a non-ischaemic minimally invasive ablative method, as nephron-sparing surgery gives excellent oncological outcomes and preserves renal function. PATIENTS AND METHODS Healthy (American Society of Anesthesiologists, ASA, I and II) patients with cT1a renal masses were identified, and clinical and radiographic data were reviewed to assess indications, complications, radiological evidence of disease recurrence, and renal function. Changes in GFR were calculated. Radiological recurrence was defined as any new enhancement (>10 Hounsfield units) after absence of enhancement on initial 6-week computed tomography. RESULTS Four patients were ASA I and 59 were ASA II; the median (range) age was 58 (20-84.6) years and the lesion diameter 2.1 (1-4.0) cm. Preoperative needle biopsy was diagnostic in 89% of patients, including 75% diagnostic of renal cell carcinoma (RCC). At a median (range) follow-up of 34 (1.0-80) months the renal preservation rate was 97%. One patient had a nephrectomy for biopsy-confirmed recurrence of RCC at 55 months; a second had a nephrectomy at 24 months for suspected radiographic recurrence, but had no evidence of disease on final pathology. A fifth (20%) of the patients had chronic kidney disease at the time of diagnosis. The median GFR before and after RFA was 76.3 and 74.3 mL/min/m2 (difference 2.0 mL/min/m2). CONCLUSION RFA might be a reasonable treatment choice for the healthy patient, with appropriate informed consent. Intermediate results suggest excellent oncological outcomes and preservation of renal function.

AB - OBJECTIVES To present the glomerular filtration rate (GFR) and oncological outcomes in a series of patients with cT1a renal cortical tumours treated with radiofrequency ablation (RFA), a non-ischaemic minimally invasive ablative method, as nephron-sparing surgery gives excellent oncological outcomes and preserves renal function. PATIENTS AND METHODS Healthy (American Society of Anesthesiologists, ASA, I and II) patients with cT1a renal masses were identified, and clinical and radiographic data were reviewed to assess indications, complications, radiological evidence of disease recurrence, and renal function. Changes in GFR were calculated. Radiological recurrence was defined as any new enhancement (>10 Hounsfield units) after absence of enhancement on initial 6-week computed tomography. RESULTS Four patients were ASA I and 59 were ASA II; the median (range) age was 58 (20-84.6) years and the lesion diameter 2.1 (1-4.0) cm. Preoperative needle biopsy was diagnostic in 89% of patients, including 75% diagnostic of renal cell carcinoma (RCC). At a median (range) follow-up of 34 (1.0-80) months the renal preservation rate was 97%. One patient had a nephrectomy for biopsy-confirmed recurrence of RCC at 55 months; a second had a nephrectomy at 24 months for suspected radiographic recurrence, but had no evidence of disease on final pathology. A fifth (20%) of the patients had chronic kidney disease at the time of diagnosis. The median GFR before and after RFA was 76.3 and 74.3 mL/min/m2 (difference 2.0 mL/min/m2). CONCLUSION RFA might be a reasonable treatment choice for the healthy patient, with appropriate informed consent. Intermediate results suggest excellent oncological outcomes and preservation of renal function.

KW - Cell death

KW - NADH diaphorase

KW - Pathology

KW - Renal cell carcinoma

KW - RFA

UR - http://www.scopus.com/inward/record.url?scp=69249125374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249125374&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2009.08443.x

DO - 10.1111/j.1464-410X.2009.08443.x

M3 - Article

VL - 104

SP - 786

EP - 789

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 6

ER -